Clinical Trial Update: Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update on tolerability and safety of IGI, 10% with rHuPH20 in primary immunodeficiency diseases; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• IGI, 10% with rHuPH20

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2017-04-24